Recent legal changes, introduced by EA PO, allows to include national patents in the EA pharmaceutical registry (active from March 2021); however, not every member country is yet willing to submit actual information on its patents. Therefore, national registries of pharmaceutical patents are still necessary.
Russian registry is still in its prototype stage and it is expected that legal framework shall be finished soon. Yury Zubov, head of RU PTO, recently stressed a necessity of parallel registry, deriving from experience, already available in EAPO. The head of the latter, Grigory Ivliev, confirmed the EA legal base is ready and theoretically every claimant may add a national patent to EA registry. But not all national PTOs are willing to provide restricted information on the patents, so the registry is doomed to be incomplete till then.
The recent changes to Russia's intellectual property laws have made it more important than ever…
The Eurasian Patent Office (EAPO) has demonstrated remarkable progress in the first six months of…
The Intellectual Property Court recognized that a distributor’s seizure of a foreign trademark constituted unfair…
Patentica is grateful for the opportunity to join INTA 2025 Annual Meeting—the world’s premier intellectual…
The Republic of Kazakhstan has officially recognized the Eurasian Patent Organization (EAPO) as an International…
Rospatent refused registration of the trademark “Milk Wave’s” (Russian trademark application No. 2022775326) submitted by the…